Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Cash & Equivalents: 2016-2025

Historic Cash & Equivalents for Organogenesis Holdings (ORGO) over the last 6 years, with Sep 2025 value amounting to $63.7 million.

  • Organogenesis Holdings' Cash & Equivalents fell 32.43% to $63.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.7 million, marking a year-over-year decrease of 32.43%. This contributed to the annual value of $135.6 million for FY2024, which is 30.56% up from last year.
  • According to the latest figures from Q3 2025, Organogenesis Holdings' Cash & Equivalents is $63.7 million, which was down 12.77% from $73.1 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' Cash & Equivalents registered a high of $135.6 million during Q4 2024, and its lowest value of $63.7 million during Q3 2025.
  • In the last 3 years, Organogenesis Holdings' Cash & Equivalents had a median value of $89.9 million in 2024 and averaged $94.1 million.
  • Per our database at Business Quant, Organogenesis Holdings' Cash & Equivalents surged by 35.00% in 2021 and then crashed by 32.43% in 2025.
  • Organogenesis Holdings' Cash & Equivalents (Quarterly) stood at $113.9 million in 2021, then fell by 10.05% to $102.5 million in 2022, then grew by 1.33% to $103.8 million in 2023, then spiked by 30.56% to $135.6 million in 2024, then plummeted by 32.43% to $63.7 million in 2025.
  • Its Cash & Equivalents stands at $63.7 million for Q3 2025, versus $73.1 million for Q2 2025 and $110.0 million for Q1 2025.